Arwa LLC Buys Shares of 5,990 Amgen Inc. $AMGN

Arwa LLC bought a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 5,990 shares of the medical research company’s stock, valued at approximately $1,960,000. Amgen accounts for approximately 1.1% of Arwa LLC’s portfolio, making the stock its 17th largest holding.

Other institutional investors have also modified their holdings of the company. High Note Wealth LLC lifted its holdings in shares of Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the last quarter. TAGStone Capital Inc. increased its holdings in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC raised its position in shares of Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management raised its position in shares of Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after purchasing an additional 29 shares during the last quarter. Finally, West Family Investments Inc. boosted its stake in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on AMGN shares. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Truist Financial upped their target price on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research report on Friday, May 1st. The Goldman Sachs Group set a $389.00 price target on Amgen in a research report on Friday, June 5th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Finally, Guggenheim cut their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Price Performance

Shares of AMGN opened at $337.60 on Friday. The stock has a 50 day moving average price of $340.71 and a 200 day moving average price of $345.76. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.